It is evident from the studies in which therapeutic inhibition of ERK1/2 reduce the expression of MMPs and delays growth and invasion tumors, including acute myeloid leukemia (AML) (48, 53). This evidence concerns the gene MAPK3 and acute myeloid leukemia.